Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04836832
Title Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Narendranath Epperla
Indications
Therapies
Age Groups: adult | senior
Covered Countries


No variant requirements are available.